Funding cutting-edge research for all forms of cancer Funds Matched by Bristol-Myers Squibb for a Total of $1.3 Million to be used for Breakthrough Cancer Research
Treatment with Velcade (bortezomib) following induction chemotherapy and stem cell transplantation seemed safe and effective for untreated patients with mantle cell lymphoma, encouraging further evaluation for more active, less toxic targeted agents.
An essay on seeing cancer from a childhood treehouse.
Four years' worth of high-stakes scans have made me an expert in four excellent ways to ease intense anxiety.
Take a look at content from CURE Magazine from 10 years ago to see how the myeloma space – and our magazine in general – has changed!
In the general population, African Americans tend to have poorer myeloma outcomes; however, that may not be the case for veterans.
Our habits can support our ability to find joy.
Tis the season to be jolly! Here are some ways to support a loved one with cancer during this festive wintertime.
In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), high doses of curcumin and vitamin D could help stabilize the disease, according to new research presented at the American Society of Hematology’s (ASH) Annual Meeting in San Diego.
Having a health care directive in your medical records is one favor you can do your family, and in some of the most unexpected and unavoidable times, they will be grateful you have it.
The Food and Drug Administration has approved Tecentriq (atezolizumab) for use in combination with Avastin (bevacizumab), carboplatin, paclitaxel, the treatment combination known as ABCP, for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
A recent study looked at a new combination to determine what would happen if untreated patients eligible for transplant were given alternating cycles of Rituxan plus bendamustine and Rituxan plus cytarabine as induction therapy. The study pooled findings from two clinical trials and real-world experience.
Once you or someone you love has been diagnosed with something big, the times between scans become sacred in-between times where you do your best to live in light of the ever-changing circumstances of your body. Sometimes that can be a time full of fear, but others it is a time full of hope.
I spend so much time trying to go back to the past or predict the future that I tend to forget how to live in today's moments.
In the MEASURE trial, researchers examined the affect symptom burden associated with myeloproliferative neoplasms has on patients’ lives.
Long-term follow-up of the JULIET trial showed patients with relapsed or refractory DLBCL continued to experience durable responses 19 months after treatment.
Feelings of sadness and depression are common among those affected by cancer, but there may be another reason behind those feelings.
Especially during holiday seasons, we remember loved ones who are not with us. Even long after they have passed, we can cherish old memories and even make new ones with the help of social media. Recently I learned something sweet about my brother John, who died of Hodgkin's lymphoma decades ago, from a high school friend I never knew about.
Treatment with Xarelto (rivaroxaban) may reduce the risk for developing blood clots during active treatment with a systemic therapy like chemotherapy, according to results from the CASSINI trial.
The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
A new program offers counseling, patient education and vetted referrals to patients and their families.
Maintenance treatment with Lynparza (olaparib) after chemotherapy has been found to significantly extend progression-free survival in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation, according to a recent phase 3 study.
Emotions are not an either/or proposition when it comes to metastatic cancer.
Administering Imbruvica with CAR-T cell therapy improved outcomes in patients with chronic lymphocytic leukemia, according to recent research.
Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.
The challenge of caring for yourself and your child while dealing with cancer is daunting.
An oncologist and three advocates were honored for their work on behalf of people with chronic lymphocytic leukemia.
A retrospective study found that clinical trials may have fewer reported side effects than the real world.
A new television show, as well as a recent CURE campaign, gave insight to life with cancer.
Here are the top 5 CURE stories for November 2018.
